RicketsSymptoms, Doctors, Treatments, Advances & More
Learn About Rickets
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Duke Endocrinology Clinic - Clinic 1A
Thomas Weber is an Endocrinologist practicing medicine in Durham, North Carolina. He has been practicing medicine for over 37 years. Dr. Weber is rated as an Elite provider by MediFind in the treatment of Rickets. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Hypophosphatemia, Rickets, X-Linked Hypophosphatemia, Malnutrition, and Parathyroidectomy. Dr. Weber is board certified in American Board Of Internal Med, Endocrinology, Diabetes & Meta.
Yale University School Of Medicine
Karl Insogna is an Endocrinologist practicing medicine in New Haven, Connecticut. Dr. Insogna is rated as an Elite provider by MediFind in the treatment of Rickets. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses X-Linked Hypophosphatemia, Hypophosphatemia, Rickets, Parathyroidectomy, and Hormone Replacement Therapy (HRT).
UVA Health Midlife Health And Gynecologic Specialties Northridge
Suzanne Jan De Beur is an Endocrinologist practicing medicine in Charlottesville, Virginia. Dr. Jan De Beur is rated as an Elite provider by MediFind in the treatment of Rickets. She is also highly rated in 20 other conditions, according to our data. Her clinical expertise encompasses Rickets, Osteomalacia, Hypophosphatemia, and X-Linked Hypophosphatemia.
Summary: FGF23 is the cornerstone of phosphate / calcium / vitamin D metabolism: it is synthesized mainly by osteocytes and acts as a phosphaturizing agent, inhibitor of dihydroxyvitamin D, and inhibitor of synthesis and secretion of PTH in most tissues. The specific role of FGF23 on bone has yet to be demonstrated. In osteoblasts, overexpression of FGF23 in vitro suppresses not only osteoblastic different...
Summary: This study has four objectives: 1) to provide investigators the opportunity to study bone specimens from patients with various skeletal diseases; 2) to treat patients with skeletal diseases at the NIH; 3) to expose NIH trainees to certain skeletal diseases; and 4) to gain more knowledge about skeletal diseases and stimulate further study of bone biology. Anyone with a disease that affects the skel...